MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants

MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants

Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and mod...

Full description

Saved in:
Bibliographic Details
Main Authors: Sua Lee, Shina Jang, Jihoon Kang, Soo Bin Park, Young Woo Han, Hyemi Nam, Munkyung Kim, Jeewon Lee, Ki Joon Cho, Jeonghun Kim, Miyoung Oh, Jihye Ryu, Jong Hyeon Seok, Yunhwa Kim, Jee-Boong Lee, Man-Seong Park, Yong-Sung Kim, Hosun Park, Dong-Sik Kim
Format: article
Language:EN
Published: Frontiers Media S.A. 2021
Subjects:
MG1141A
SARS-CoV-2
monoclonal antibody
outbreak
spike protein
Immunologic diseases. Allergy
RC581-607
Online Access:https://doaj.org/article/7e740e1bfe9248e3844839c81b27bd6d
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items